CD4 and cancer: While it is important to note that TSCM represent a small proportion of the total circulating CD4+ T-cells and their level of infection was relatively low, demonstration of their susceptibility to infection by both R5 and X4 clinical C-HIV viruses provides new information that may help inform the design and implementation of therapies that target the TSCM HIV-1 reservoir, such as anti-cancer drugs that block stem cell-specific molecular pathways expressed by TSCM cells [25].